New drugs for the treatment of metastatic colorectal cancer

Cherri, Sara; Libertini, Michela; Zaniboni, Alberto

doi:10.4251/wjgo.v13.i11.1551

Cited by 3 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At least half of the patients with diagnosed CRC will develop metastatic CRC (mCRC) ( 2 ). Despite recent advances in systemic treatment options and surgical management strategies ( 3 , 4 ) prognosis of mCRC remains grim, with a relative 5‐year survival rate of only 14% ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients

et al. 2022

View full text Add to dashboard Cite

Cell surface syndecans and glypicans play important roles in the development and prognosis of colorectal cancer (CRC). Their soluble forms from proteoglycan shedding can be detected in blood and have been proposed as new prognostic biomarkers in several cancer entities. However, studies on circulating syndecan-1 (SDC1) and glypican-4 (GPC4) in CRC are limited. We, therefore, evaluated the impact of plasma SDC1 and GPC4 on the prognosis of metastatic (m)CRC patients. The present study included 93 patients with mCRC. The endpoints were progression-free survival (PFS) and overall survival (OS) at 12 months. SDC1 and GPC4 levels were measured in plasma using enzyme-linked immunosorbent assays. Plasma levels of SDC1 and GPC4 were significantly correlated. Significant correlations of these two markers were also found with carcinoembryonic antigen (CEA). Kaplan-Meier curve analyses indicated that PFS and OS probabilities significantly decreased with increasing levels of SDC1 and GPC4, respectively. Multivariable Cox regression analyses showed that both markers were significantly associated with PFS and OS independently from clinicopathological characteristics including CEA. Respective adjusted hazard ratios (HR) together with corresponding 95% confidence intervals for one standard deviation change of SDC1 were 1.32 [1.02-1.84] for PFS and 1.48 [1.01-2.15] for OS. Adjusted HRs [95% confidence intervals] of GPC4 were 1.42 [1.07-1.89] for PFS and 2.40 [1.51-3.81] for OS. Results from area under the receiver operating characteristic curve analyses suggest that GPC4 and SDC1 add additional prognostic values to CEA for OS. In conclusion, we showed significant associations of circulating SDC1 and GPC4 with poor survival of mCRC patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…There are many challenges in expanding potential treatment options, in particular, better understanding the biology of the disease and the resistance mechanisms underlying cancer treatment failure. The development of new drugs is certainly one of the most important challenges in oncology [46].…”

Section: Activity Toward Colorectal Cancer Cellsmentioning

confidence: 99%

“…The amount of Raptor, Rictor and GβL, p-PRAS40, 4E-BP1, eIF4E and p70S6K is also significantly reduced. Thus, PI3K signaling is clearly influenced by FIS, and the effect seems to be additionally enhanced by 5-FU [46]. FIS also inhibits Wnt signaling activity by downregulating β-catenin and T4 cell factor, and inhibits the activation of EGFR and nuclear kappa factor B (NF-κB).…”

Section: Activity Toward Colorectal Cancer Cellsmentioning

confidence: 99%

Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review

et al. 2022

View full text Add to dashboard Cite

Diet plays a crucial role in homeostasis maintenance. Plants and spices containing flavonoids have been widely used in traditional medicine for thousands of years. Flavonols present in our diet may prevent cancer initiation, promotion and progression by modulating important enzymes and receptors in signal transduction pathways related to proliferation, differentiation, apoptosis, inflammation, angiogenesis, metastasis and reversal of multidrug resistance. The anticancer activity of fisetin has been widely documented in numerous in vitro and in vivo studies. This review summarizes the worldwide, evidence-based research on the activity of fisetin toward various types of cancerous conditions, while describing the chemopreventive and therapeutic effects, molecular targets and mechanisms that contribute to the observed anticancer activity of fisetin. In addition, this review synthesized the results from preclinical studies on the use of fisetin as an anticancer agent. Based on the available literature, it might be suggested that fisetin has a bioactive potential to become a complementary drug in the prevention and treatment of cancerous conditions. However, more in-depth research is required to validate current data, so that this compound or its derivatives can enter the clinical trial phase.

show abstract

“…Thus, new treatment options, such as targeted therapies, are urgently needed. Fortunately, advances in understanding the biology of the disease and in the development of cost-effective technologies that can precisely determine the molecular profiling of the disease will allow us to develop various targeted therapies against CRC, particularly metastatic CRC [3] , some of which have been used to treat CRC in the clinic [ 2 , 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis

et al. 2022

View full text Add to dashboard Cite

New drugs for the treatment of metastatic colorectal cancer

Cited by 3 publications

References 46 publications

Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients

Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients

Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review

Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis

Contact Info

Product

Resources

About